Investor Relations

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Feb 29, 2024
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
Feb 27, 2024
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Feb 16, 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 03, 2024
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
Jan 31, 2024
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Stern Investor Relations
p. 212.362.1200

Amy Phillips
p. 412.327.9499